ProFibrix
Innovative products for the hemostasis and regenerative medicine markets.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD327m (Public information from Aug 2013)
Seattle Washington (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$11.0m | Series A | ||
$11.4m | Series B | ||
$10.6m | Series B | ||
$240m Valuation: $240m | Acquisition | ||
| Total Funding | CAD45.0m | ||